University of Sheffield spinout Rinri Therapeutics has collected $13.9m from investors including Boehringer Ingelheim Venture Fund and UCB Ventures.
Rinri Therapeutics, a UK-based developer of stem cell therapy to restore hearing based on research at University of Sheffield, has pocketed £10m ($13.9m) from investors including pharmaceutical firms Boehringer Ingelheim and UCB Pharma.
BioCity and the UK government’s Future Fund also took part in the round. The two corporates invested through Boehringer Ingelheim Venture Fund (BIVF) and UCB Ventures, respectively.
Rinri is working on a treatment for sensorineural hearing loss – caused by damage to the hair cells…
